Blood Glucose Determinations Differ in Plasma and Serum
|
By LabMedica International staff writers Posted on 05 Jul 2012 |
|
Blood glucose determination is one of the most common clinical diagnostic tests and accurate and precise measurement of blood glucose is of great importance in the diagnosis and management of diabetes.
The concentration of glucose in the blood will continue to decrease over time after phlebotomy because of glycolysis, which will occur in erythrocytes, white blood cells (WBCs), and platelets as these cells can continue to metabolize glucose.
Laboratory scientists at the University of Mysore, (Manasagangotri, India) investigated the effect of time and the method of processing of blood on the blood glucose levels. Blood from 30 different patients who came for routine blood glucose determination were used in the study. Whole blood was divided into three portions. One portion was allowed to clot. To the second portion, 2mg/mL sodium fluoride was added, and to the third portion, ethylene diamine tetra acetic acid (EDTA)–disodium salt was added.
Blood sugar was estimated using a blood sugar assay kit (Becton Dickinson, Bangalore, India). Optical Density (OD) of the colored complex was measured at 620 nm in an autoanalyzer. Blood sugar in these samples stored at room temperature was measured again after four hours and eight hours. The serum gave values lower than fluoride plasma by 1.15%. Although this difference was statistically significant, it may not be physiologically relevant. On storing the sample at room temperature for eight hours, the serum glucose value decreased by 8% and even fluoride plasma had 4.3% lower glucose.
The authors concluded that blood glucose should be determined within as short a time as possible after drawing the blood. The blood glucose values ranged from 76 to 410 mg/dL covering a wide range of blood glucose values that would be seen in any sample analysis. Serum may be a better sample for blood glucose determination particularly when there is a time delay in the measurement. If appropriate correction is applied, it may actually be a better sample than plasma. Moreover, many clinical analysis procedures require serum rather than plasma and therefore one single drawing of blood may suffice for even blood glucose estimation. The study was published online on May 14, 2012, in the Journal of Clinical Laboratory Analysis.
Related Links:
University of Mysore
Becton Dickinson
 Assay.jpg)
The concentration of glucose in the blood will continue to decrease over time after phlebotomy because of glycolysis, which will occur in erythrocytes, white blood cells (WBCs), and platelets as these cells can continue to metabolize glucose.
Laboratory scientists at the University of Mysore, (Manasagangotri, India) investigated the effect of time and the method of processing of blood on the blood glucose levels. Blood from 30 different patients who came for routine blood glucose determination were used in the study. Whole blood was divided into three portions. One portion was allowed to clot. To the second portion, 2mg/mL sodium fluoride was added, and to the third portion, ethylene diamine tetra acetic acid (EDTA)–disodium salt was added.
Blood sugar was estimated using a blood sugar assay kit (Becton Dickinson, Bangalore, India). Optical Density (OD) of the colored complex was measured at 620 nm in an autoanalyzer. Blood sugar in these samples stored at room temperature was measured again after four hours and eight hours. The serum gave values lower than fluoride plasma by 1.15%. Although this difference was statistically significant, it may not be physiologically relevant. On storing the sample at room temperature for eight hours, the serum glucose value decreased by 8% and even fluoride plasma had 4.3% lower glucose.
The authors concluded that blood glucose should be determined within as short a time as possible after drawing the blood. The blood glucose values ranged from 76 to 410 mg/dL covering a wide range of blood glucose values that would be seen in any sample analysis. Serum may be a better sample for blood glucose determination particularly when there is a time delay in the measurement. If appropriate correction is applied, it may actually be a better sample than plasma. Moreover, many clinical analysis procedures require serum rather than plasma and therefore one single drawing of blood may suffice for even blood glucose estimation. The study was published online on May 14, 2012, in the Journal of Clinical Laboratory Analysis.
Related Links:
University of Mysore
Becton Dickinson
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Thyroid Test
Anti-Thyroid EIA Test
HPV Molecular Test
BD Onclarity HPV Assay
Latest Clinical Chem. News
- Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing
- Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
- Blood Biomarker Reveals Hidden Disability Progression in Multiple Sclerosis
- Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
- Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
- Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
- Blood Protein Panel Predicts Timing of ALS Symptom Onset
- Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
- Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
- New Machine-Learning Equation Improves LDL Cholesterol Assessment
- Ultrasensitive Biosensor Detects Early Liver Fibrosis from Blood
- Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
- Blood Test Improves Alzheimer’s Diagnosis Across Care Settings
- New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
- Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
- Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
Channels
Molecular Diagnostics
view channel
Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy
Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more
Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings
Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more
Hematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more
Immunology
view channel
Study Reveals Viral Protein Driving COVID-19-Related Vascular Injury
Lingering symptoms after acute COVID-19 infection remain a clinical challenge, with many patients experiencing fatigue, cognitive problems, and cardiovascular complications months later.... Read more
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Microbiology
view channel
Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more
Proteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
The intestinal microbiome influences digestion, metabolism, and immunity, yet its complexity makes functional measurements difficult to obtain. DNA surveys can indicate which organisms and potential pathways... Read more
Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
Serious lung infections remain a major cause of morbidity among people with cystic fibrosis, a life-threatening genetic disorder characterized by persistent airway colonization and frequent antimicrobial exposure.... Read more
Pathology
view channel
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more
